Peptide-Based Vaccine Against Breast Cancer: Recent Advances and Prospects

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Jul 29

PMID 37513835

Authors

Muhammad Luqman Nordin

Ahmad Khusairi Azemi

Abu Hassan Nordin

Walid Nabgan

Pei Yuen Ng

Khatijah Yusoff

Nadiah Abu

Kue Peng Lim

Zainul Amiruddin Zakaria

Noraznawati Ismail

Fazren Azmi

Affiliations

Soon will be listed here.

Abstract

Breast cancer is considered the second-leading cancer after lung cancer and is the most prevalent cancer among women globally. Currently, cancer immunotherapy via vaccine has gained great attention due to specific and targeted immune cell activity that creates a potent immune response, thus providing long-lasting protection against the disease. Despite peptides being very susceptible to enzymatic degradation and poor immunogenicity, they can be easily customized with selected epitopes to induce a specific immune response and particulate with carriers to improve their delivery and thus overcome their weaknesses. With advances in nanotechnology, the peptide-based vaccine could incorporate other components, thereby modulating the immune system response against breast cancer. Considering that peptide-based vaccines seem to show remarkably promising outcomes against cancer, this review focuses on and provides a specific view of peptide-based vaccines used against breast cancer. Here, we discuss the benefits associated with a peptide-based vaccine, which can be a mainstay in the prevention and recurrence of breast cancer. Additionally, we also report the results of recent trials as well as plausible prospects for nanotechnology against breast cancer.

Citing Articles

Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.

Mitra A, Kumar A, Amdare N, Pathak R Biology (Basel). 2024; 13(5).

PMID: 38785789 PMC: 11118874. DOI: 10.3390/biology13050307.

Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.

Hargrave A, Mustafa A, Hanif A, Tunio J, Hanif S Vaccines (Basel). 2023; 11(11).

PMID: 38005965 PMC: 10675687. DOI: 10.3390/vaccines11111633.

References

Yamaguchi Y, Yamaue H, Okusaka T, Okuno K, Suzuki H, Fujioka T . Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014; 105(7):924-31. PMC: 4317908. DOI: 10.1111/cas.12443. View

Synnott N, Bauer M, Madden S, Murray A, Klinger R, ODonovan N . Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2017; 414:99-106. DOI: 10.1016/j.canlet.2017.09.053. View

Apostolopoulos V, Pietersz G, Tsibanis A, Tsikkinis A, Drakaki H, Loveland B . Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006; 8(3):R27. PMC: 1557739. DOI: 10.1186/bcr1505. View

Lyu H, Huang J, He Z, Liu B . Epigenetic mechanism of survivin dysregulation in human cancer. Sci China Life Sci. 2018; 61(7):808-814. PMC: 6050049. DOI: 10.1007/s11427-017-9230-2. View

Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H . WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008; 20(2):211-20. DOI: 10.1016/j.coi.2008.04.009. View

Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H . Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101(38):13885-90. PMC: 518848. DOI: 10.1073/pnas.0405884101. View

Qi X, Zhang F, Wu H, Liu J, Zong B, Xu C . Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015; 5:8924. PMC: 4352850. DOI: 10.1038/srep08924. View

Patil R, Clifton G, Holmes J, Amin A, Carmichael M, Gates J . Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg. 2010; 210(2):140-7. DOI: 10.1016/j.jamcollsurg.2009.10.022. View

Gokmen-Polar Y, Toroni R, Hocevar B, Badve S, Zhao Q, Shen C . Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat. 2010; 127(2):375-84. DOI: 10.1007/s10549-010-1004-y. View

10.

Salem A, Wang S, Billet S, Chen J, Udompholkul P, Gambini L . Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem. 2018; 61(5):2052-2061. PMC: 5907794. DOI: 10.1021/acs.jmedchem.7b01837. View

11.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

12.

Guo Z, He B, Yuan L, Dai W, Zhang H, Wang X . Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers. Int J Pharm. 2015; 493(1-2):380-9. DOI: 10.1016/j.ijpharm.2015.05.051. View

13.

Shiomi A, Usui T . Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015; 2015:568543. PMC: 4370199. DOI: 10.1155/2015/568543. View

14.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

15.

Turriziani M, Fantini M, Benvenuto M, Izzi V, Masuelli L, Sacchetti P . Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov. 2012; 7(3):265-96. DOI: 10.2174/157489212801820020. View

16.

Kalli K, Block M, Kasi P, Erskine C, Hobday T, Dietz A . Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res. 2018; 24(13):3014-3025. PMC: 6030477. DOI: 10.1158/1078-0432.CCR-17-2499. View

17.

Nezafat N, Ghasemi Y, Javadi G, Khoshnoud M, Omidinia E . A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. 2014; 349:121-34. DOI: 10.1016/j.jtbi.2014.01.018. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Wimmers F, De Haas N, Scholzen A, Schreibelt G, Simonetti E, Eleveld M . Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. Sci Rep. 2017; 7:43486. PMC: 5361210. DOI: 10.1038/srep43486. View

20.

Santoni D . Viral peptides-MHC interaction: Binding probability and distance from human peptides. J Immunol Methods. 2018; 459:35-43. DOI: 10.1016/j.jim.2018.05.009. View